You are here

Press Release Archive

 
May 18, 2016 - Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

Merck KGaA, Darmstadt, Germany, and Pfizer today announced that avelumab* presentations across seven different tumor types, including two oral presentations, will be featured at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3–7, 2016, in Chicago, IL.

 
May 18, 2016 - Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Pfizer Inc. (NYSE:PFE) today announced that the company will have its largest presence to date at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7, with more than 40 abstracts spanning a diverse and growing portfolio seeking to tackle numerous cancers and mechanisms of action. Presentations include eight oral presentations and five poster discussions that span Pfizer’s internal and collaborative scientific advances.

 
May 17, 2016 - Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA)

Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management.

 
May 16, 2016 - Pfizer to Acquire Anacor

Pfizer Inc. (NYSE:PFE) and Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes.

 
May 13, 2016 - Pfizer Presents Results from Two Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Studies at the European Society for Paediatric Infectious Diseases Meeting

Pfizer Inc. (NYSE:PFE) today announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints. Also, secondary data presented show that TRUMENBA demonstrated similar immune responses against ten additional MnB strains, in both adolescents and young adults.

 
May 11, 2016 - Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative

Pfizer Inc. (NYSE:PFE) today announced that it has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies. The awards are part of Pfizer’s Breast Cancer: A Story Half Told initiative, aimed at uncovering gaps in the public’s knowledge of MBC and bringing greater attention to the unique needs and experiences of people living with this disease.

 
May 3, 2016 - PFIZER REPORTS FIRST-QUARTER 2016 RESULTS
Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:
 
April 28, 2016 - Pfizer Hosts Annual Meeting of Shareholders

The board of directors of Pfizer Inc. today declared a 30-cent second-quarter 2016 dividend on the company’s common stock, payable June 1, 2016, to shareholders of record at the close of business on May 13, 2016.

 
April 26, 2016 - Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled

Pfizer Inc. today announced patient enrollment completion in the global SPIRE-2 cardiovascular outcome trial for its investigational agent bococizumab.

 
April 22, 2016 - CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet

Pfizer Inc. (NYSE:PFE) today announced results published in The Lancet from the largest clinical trial of approved smoking cessation medicines, called EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study).

 
April 21, 2016 - Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 28, 2016.

 
April 7, 2016 - Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care

NEW YORK & ARMONK, N.Y.--Pfizer Inc. (NYSE:PFE) and IBM (NYSE:IBM) today announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient’s disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options.

 
April 6, 2016 - Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®

NEW YORK--Pfizer Inc. (NYSE:PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). This new MDV presentation was developed to help maximize efficiency for health care workers by helping to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing.

 
April 6, 2016 - Pfizer Announces Termination of Proposed Combination with Allergan

NEW YORK, N.Y., April 6 - Pfizer Inc. (NYSE: PFE) today announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.

 
April 5, 2016 - FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

NEW YORK--The United States (U.S.) Food and Drug Administration (FDA) today approved Celltrion’s INFLECTRA™ (biosimilar infliximab) across all eligible indications of the reference product, Remicade® (infliximab).1INFLECTRA is now the first and only biosimilar monoclonal antibody (mAb) therapy, and only the second biosimilar, to be approved in the U.S.

 
April 5, 2016 - Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinom

DARMSTADT, Germany & NEW YORK--Merck and Pfizer (NYSE:PFE) today announced the treatment of the first patient in a Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal ant

 
April 5, 2016 - Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

NEW YORK, N.Y., April 5 – Pfizer Inc. announced today top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic arthritis, Oral Psoriatic Arthritis triaL (OPAL) Broaden.

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.